International Urogynecology Journal

, Volume 21, Issue 3, pp 321–324 | Cite as

Intravesical lignocaine in the diagnosis of bladder pain syndrome

Original Article

Abstract

Introduction and hypothesis

To differentiate between the pain originating from urinary bladder and that due to other pelvic organs, using intravesical instillations of 2% lignocaine solution.

Methods

Twenty-two women with pelvic pain received intravesical instillation of 20 ml of 2% lignocaine solution. The intensity of pain was recorded by using visual analogue scale (VAS) just before, at 2, 10 and 20 min after intravesical instillation. Women who experienced a drop in the VAS score by 50% were termed as responders. All these women underwent cystoscopy under anaesthesia.

Results

Fifteen out of 22 (68.18%) women experienced a substantial reduction in the pain. Thirteen out of these 15 women had features suggestive of BPS/IC on cystoscopy. Out of the seven non-responders, two women were found to have endometriosis, four were diagnosed as pelvic inflammatory disease and one had diverticulitis.

Conclusions

Intravesical lignocaine appears to be useful in excluding patients with pelvic pain originating from organs other than the urinary bladder.

Keywords

Bladder pain syndrome Intravesical lignocaine 

Abbreviations

BPS

Bladder pain syndrome

IC

Interstitial cystitis

VAS

Visual analogue scale

References

  1. 1.
    Parsons CL (2004) Diagnosing chronic pelvic pain of bladder origin. J Reprod Med 49(3 Suppl):235–242PubMedGoogle Scholar
  2. 2.
    Evans RJ, Stanford EJ (2006) Current issues in the diagnosis of painful bladder syndrome/interstitial cystitis. J Reprod Med 51(3 Suppl):241–252PubMedGoogle Scholar
  3. 3.
    Asklin B, Cassuto J (1989) Intravesical lidocaine in severe interstitial cystitis. Scand J Urol Nephrol 23(4):311–312PubMedCrossRefGoogle Scholar
  4. 4.
    Parsons CL (2005) Successful down regulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology 65:45–48CrossRefPubMedGoogle Scholar
  5. 5.
    Taneja R, Jawade KK (2007) Rational combination of intravesical and systemic agents for the treatment of interstitial cystitis. Scand J Urol Nephrol 41(6):511–515CrossRefPubMedGoogle Scholar
  6. 6.
    Ibrahim IA, Diokno AC, Killinger KA et al (2007) Prevalence of self-reported interstitial cystitis (IC) and interstitial-cystitis-like symptoms among adult women in the community. Int Urol Nephrol 39(2):489–495CrossRefPubMedGoogle Scholar
  7. 7.
    Kushner L, Moldwin RM (2006) Efficiency of questionnaires used to screen for interstitial cystitis. J Urol 176(2):587–592CrossRefPubMedGoogle Scholar
  8. 8.
    Giannakopoulos X, Champilomatos P (1992) Chronic interstitial cystitis: successful treatment with intravesical lidocaine. Arch Ital Urol Nefrol Androl 64:337–339PubMedGoogle Scholar
  9. 9.
    Seth A, Teichmann JMH (2008) What's new in the diagnosis and management of painful bladder syndrome/interstitial cystitis. Curr Urol Rep 9:349–357CrossRefPubMedGoogle Scholar
  10. 10.
    Henry R, Patterson L, Avery N et al (2001) Absorption of alkalized intravesical lidocaine in normal and inflamed bladders: a simple method for improving bladder anesthesia. J Urol 165:1900–1903CrossRefPubMedGoogle Scholar
  11. 11.
    Oh SJ, Paick SH, Lim DJ et al (2005) Effects of local anesthetics on human bladder contractility. Neurourol Urodyn 24(3):288–294CrossRefPubMedGoogle Scholar
  12. 12.
    Wewers ME, Lowe NK (1990) A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health 13:227–236CrossRefPubMedGoogle Scholar

Copyright information

© The International Urogynecological Association 2009

Authors and Affiliations

  1. 1.Pushpawati Singhania Research InstituteNew DelhiIndia

Personalised recommendations